Global Viral Inactivation Market Report and Forecast 2023-2031

Global Viral Inactivation Market Report and Forecast 2023-2031

Global Viral Inactivation Market Outlook:

The global viral inactivation market value was USD 615.8 million in 2022, driven by the need to eliminate viral contaminants from biopharmaceutical products across the globe. The market size is anticipated to grow at a CAGR of 11.5% during the forecast period of 2023-2031 to achieve a value of USD 1640 million by 2031.

Introduction

Viral inactivation is a critical process used in the manufacturing of biopharmaceutical products to ensure the elimination or inactivation of viruses present in biological materials. It involves the application of various physical or chemical methods to reduce the infectivity of viruses without significantly impacting the therapeutic properties of the product. Viral inactivation plays a crucial role in ensuring the safety of biologics, vaccines, and other therapeutic products by minimizing the risk of viral transmission to patients.

Key Trends in the Viral Inactivation Market

Some of the key trends in the market are:

Increasing Regulatory Requirements: Regulatory authorities continue to strengthen the guidelines and requirements for viral inactivation in biopharmaceutical manufacturing. There is a growing emphasis on comprehensive and effective viral inactivation methods to mitigate the risk of viral contamination. This trend is driven by the need to safeguard patient safety and ensure the quality and efficacy of therapeutic products.
Advancements in Viral Inactivation Technologies: The field of viral inactivation is experiencing continuous advancements in technologies and methods used to inactivate viruses. Newer and more efficient techniques, such as solvent-detergent treatment, heat treatment, irradiation, and filtration, are being developed and optimized to enhance viral inactivation efficacy. These advancements aim to improve the overall safety profile of biopharmaceutical products by providing robust and reliable viral inactivation.
Focus on Viral Safety in Emerging Therapies: With the emergence of novel therapeutic approaches, such as gene therapy and cell-based therapies, there is an increased focus on viral safety in these advanced treatment modalities. These therapies often involve the use of viral vectors or genetically modified cells, making viral inactivation a critical step in the manufacturing process. The development of specialized viral inactivation strategies specific to these advanced therapies is a key trend in the field.
Application of Innovative Technologies: The industry is witnessing the application of innovative technologies in viral inactivation, including the use of nanotechnology, photodynamic therapy, and plasma treatment. These technologies offer the potential for enhanced viral inactivation efficacy while minimizing the impact on product quality. The exploration and adoption of such innovative approaches contribute to the advancement of viral inactivation methods.
Integration of Viral Inactivation in Continuous Manufacturing: Continuous manufacturing is gaining momentum in the biopharmaceutical industry, and there is a growing interest in integrating viral inactivation processes within continuous manufacturing platforms. This integration aims to streamline production, reduce costs, and ensure consistent and efficient viral inactivation throughout the manufacturing process.

Viral Inactivation Market Segmentations

Market by Product

Kits and Reagents
Services
Viral Inactivation Systems and Accessories
Market by Application

Vaccines and Therapeutics
Stem Cell Products
Blood and Blood Products
Tissue and Tissue Products
Cellular and Gene Therapy
Market by End User

Pharmaceutical and Biotechnology Companies
CROs
Academic and Research Institutes
Others
Market Breakup by Region

North America
United States of America
Canada
Europe
United Kingdom
Germany
France
Italy
Others
Asia Pacific
China
Japan
India
ASEAN
Australia
Others
Latin America
Brazil
Argentina
Mexico
Others
Middle East and Africa
Saudi Arabia
United Arab Emirates
Nigeria
South Africa
Others

Viral Inactivation Market Scenario

The market is driven by the increasing need to eliminate viral contaminants from biopharmaceutical products and minimize the risk of viral transmission to patients. Regulatory authorities impose stringent guidelines and requirements for viral inactivation, necessitating the use of effective and validated viral inactivation methods. Biopharmaceutical companies invest in viral inactivation technologies and services to comply with these regulations and deliver high-quality products to the market.

Advancements in viral inactivation technologies are shaping the market, with ongoing research and development efforts focused on improving the efficacy, efficiency, and safety of viral inactivation methods. Innovative approaches such as advanced filtration techniques, non-thermal plasma treatment, and novel chemical agents are being explored to enhance the viral inactivation process. These advancements aim to provide robust and reliable viral inactivation while minimizing the impact on product quality and efficacy.

The market for viral inactivation also benefits from the integration of continuous manufacturing processes. Continuous manufacturing offers advantages such as improved process efficiency, reduced costs, and enhanced product quality control. Integrating viral inactivation within continuous manufacturing platforms enables real-time monitoring and control of the viral inactivation process, leading to streamlined production and reduced risks of contamination.

Viral Inactivation Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

Rad Source Technologies Inc
Merck KGaA
Parker Hannifin Corp
Sartorius AG
Cerus Corporation
Cytiva (Danaher Corporation)
Charles River Laboratories
CONVATEC GROUP PLC
WuXi AppTec
TERUMO BCT, INC.
Thermo Fisher Scientific Inc.
SCI Automation